A CRA expert was retained by merging parties in the pharmaceutical industry to verify merger efficiencies that were being claimed by management. CRA’s team worked with both firms to analyze and document the efficiencies analyses and verify the merger-specificity of the cost savings. For several efficiencies, CRA developed its own models of the projected cost savings. A CRA expert presented the findings to the FTC, and shortly afterward, the FTC entered into a settlement with the parties that allowed the merger to proceed while preserving the documented efficiencies.
Navigating the future of EU merger control: Insights from the “All Points of the Compass” panel at the CRA Brussels Conference 2025
The panel “All Points of the Compass: Navigating the Future of EU Merger Control” discussed the consultation review of the European Commission (EU) guidelines,